Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trillium Therapeutics has dosed the first patient in a Phase I trial evaluating TTI-1612, an investigational agent in development for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
Subscribe to our email newsletter
The study, which is being conducted at multiple sites across Southern Ontario, will evaluate the safety and pharmacokinetics of single ascending doses of TTI-1612 in IC/BPS patients.
TTI-1612 is a recombinant growth factor that is administered directly into the bladder.
It is being developed to correct the dysfunction and restore the bladder epithelium to a normal, healthy state.
Trillium drug development director Penka Petrova said the company is looking forward to expanding the program into the US and beyond with the start of its next trial in 2013.